(BUSINESS WIRE) — IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) announced today it will make a presentation at the UBS Warburg Global Life Sciences Conference on Wednesday, September 24, 2003 at 2:30 p.m. Eastern Standard Time (EST) at the Plaza Hotel in New York. The presentation will be webcast live and is accessible by using the link provided in the investor relations section of IDEC’s website (idecpharm.cdmail.biz).
IDEC Pharmaceuticals Corporation is a leader in the discovery, development, and commercialization of targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC discovered and developed the first commercially available radioimmunotherapy product (Zevalin(TM)) approved in the United States, which is used to treat certain non-Hodgkin’s lymphomas. IDEC also discovered, and with co-promotion partner Genentech, Inc., developed the first monoclonal antibody product (Rituxan((R)) approved in the United States for the treatment of cancer. Rituxan is approved in over 70 countries worldwide and is also used to treat various types of non-Hodgkin’s lymphomas. IDEC is a San Diego based, integrated biopharmaceutical company with multiple products in clinical stage development and strategic alliances in a variety of research platforms.
IDEC Pharmaceuticals, Rituxan and Zevalin are registered U.S. trademarks of the company.
The company’s headquarters are located at 3030 Callan Road, San Diego, CA 92121. For a menu of IDEC’s current news releases and quarterly reports or to retrieve a specific release, call (888) 329-2309. On the Internet check the News Center at IDEC’s website: http://idecpharm.cdmail.biz.
CONTACT: IDEC Pharmaceuticals Corporation Vince Reardon, 858-431-8656
SOURCE: IDEC Pharmaceuticals Corporation